30Aug 2023
Fluvoxamine vs. Placebo for Outpatients With Symptomatic COVID-19

Fluvoxamine vs. Placebo for Outpatients With Symptomatic COVID-19

A study examined fluvoxamine's impact on preventing COVID-19 deterioration in symptomatic patients. Conducted between Dec 2020 and May 2021, the study included 547 participants. Although clinical deterioration rates were low in both groups, fluvoxamine didn't demonstrate significant efficacy. The trial ended prematurely due to lower-than-expected event rates and vaccine availability. Results suggested that fluvoxamine might not effectively prevent COVID-19 deterioration in unvaccinated symptomatic patients.

  • #family health

Like

Save

Share